Technical Trend Evolution and Momentum Analysis
The recent technical parameter adjustments for Lupin Ltd. reveal a strengthening bullish momentum. The stock’s current price stands at ₹2,340.20, up 1.41% from the previous close of ₹2,307.55, with intraday highs touching the 52-week peak of ₹2,381.05. This price action reflects robust buying interest and a potential breakout scenario near its yearly high.
On the weekly and monthly charts, the Moving Average Convergence Divergence (MACD) indicator remains bullish, signalling sustained upward momentum. The weekly MACD confirms positive momentum with the MACD line above the signal line, while the monthly MACD corroborates this trend, reinforcing the medium-term bullish outlook. Conversely, the Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, indicating that the stock is not yet in overbought territory and may have room for further appreciation.
Bollinger Bands on weekly and monthly charts also support the bullish narrative, with price action hugging the upper band, a classic sign of strong momentum and potential continuation of the uptrend. Daily moving averages further affirm this stance, with the stock trading above its key short- and medium-term averages, signalling a positive price trajectory.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Complementary Technical Indicators and Trend Confirmation
The Know Sure Thing (KST) indicator presents a nuanced picture: weekly readings are bullish, reinforcing short-term strength, while monthly readings are mildly bearish, suggesting some caution in the longer term. This divergence highlights the importance of monitoring momentum shifts closely over coming weeks.
Dow Theory assessments on both weekly and monthly scales are mildly bullish, indicating that the broader market trend supports Lupin’s upward movement. Meanwhile, On-Balance Volume (OBV) shows a mildly bullish trend on the weekly chart but lacks a clear trend monthly, implying that volume-driven confirmation is stronger in the short term.
These mixed signals underscore a technical environment where short- to medium-term momentum is robust, but investors should remain vigilant for any shifts in longer-term indicators that could temper enthusiasm.
Comparative Performance and Market Context
From a returns perspective, Lupin Ltd. has outperformed the benchmark Sensex significantly over multiple time horizons. Year-to-date, Lupin has delivered a 10.8% return compared to the Sensex’s negative 8.87%. Over one year, Lupin’s 12.03% gain contrasts with the Sensex’s 3.06% decline. The outperformance is even more pronounced over three and five years, with Lupin returning 236.79% and 116.89% respectively, dwarfing the Sensex’s 30.19% and 62.21% gains.
Despite a more modest 10-year return of 50.19% relative to the Sensex’s 200.58%, Lupin’s recent technical upgrades and price momentum suggest a potential acceleration phase that could improve its longer-term trajectory.
Mojo Score and Rating Revision
MarketsMOJO’s proprietary scoring system currently assigns Lupin a Mojo Score of 74.0, categorising it as a Buy. This represents a slight downgrade from its previous Strong Buy rating as of 21 April 2026, reflecting a recalibration of risk and reward amid evolving technical signals. The mid-cap classification aligns with Lupin’s market capitalisation and growth profile, positioning it as a compelling candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a balanced risk-return profile.
Curious about Lupin Ltd. from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Investor Implications and Outlook
For investors, Lupin’s technical profile suggests a favourable entry point supported by strong momentum indicators and a resilient price trend. The stock’s proximity to its 52-week high of ₹2,381.05, combined with bullish MACD and Bollinger Band signals, indicates potential for further upside in the near term.
However, the absence of a clear RSI signal and the mildly bearish monthly KST reading counsel prudence, recommending that investors monitor volume trends and broader market conditions closely. The mild downgrade from Strong Buy to Buy by MarketsMOJO reflects this balanced view, acknowledging both the stock’s strengths and the need for vigilance amid sectoral and macroeconomic uncertainties.
Given Lupin’s strong historical outperformance relative to the Sensex and its current technical momentum, the stock remains an attractive proposition for mid-cap investors seeking exposure to the Pharmaceuticals & Biotechnology sector’s growth potential.
Summary of Technical Indicators
• MACD: Weekly and Monthly – Bullish, confirming sustained momentum.
• RSI: Weekly and Monthly – No signal, indicating neutral momentum.
• Bollinger Bands: Weekly and Monthly – Bullish, price near upper band.
• Moving Averages: Daily – Bullish, price above key averages.
• KST: Weekly – Bullish; Monthly – Mildly Bearish.
• Dow Theory: Weekly and Monthly – Mildly Bullish.
• OBV: Weekly – Mildly Bullish; Monthly – No clear trend.
Price and Volume Snapshot
Current Price: ₹2,340.20
Previous Close: ₹2,307.55
52-Week High: ₹2,381.05
52-Week Low: ₹1,774.00
Today’s High: ₹2,381.05
Today’s Low: ₹2,297.00
Day Change: +1.41%
Returns Comparison with Sensex
1 Week: Lupin +0.59%, Sensex -0.42%
1 Month: Lupin +1.87%, Sensex +6.83%
Year-to-Date: Lupin +10.80%, Sensex -8.87%
1 Year: Lupin +12.03%, Sensex -3.06%
3 Years: Lupin +236.79%, Sensex +30.19%
5 Years: Lupin +116.89%, Sensex +62.21%
10 Years: Lupin +50.19%, Sensex +200.58%
Conclusion
Lupin Ltd.’s recent technical upgrades and sustained bullish momentum position it favourably within the mid-cap Pharmaceuticals & Biotechnology space. While some longer-term indicators suggest caution, the overall technical landscape supports a positive near-term outlook. Investors should consider Lupin’s strong relative performance and technical signals as part of a diversified portfolio strategy, keeping an eye on evolving momentum and volume trends for confirmation.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
